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Human metallothioneins are a superfamily of low molecular weight intracellular proteins, whose synthesis can be induced 
by essential elements (primarily Zn and Cu), toxic elements and chemical agents, and stress-producing conditions. Of 
the four known isoforms in the human body MT2 is the most common. The expression of metallothioneins is encoded 
by a multigene family of linked genes and can be influenced by single nucleotide polymorphisms (SNPs) in these genes. 
To date, 24 SNPs in the MT2A gene have been identified with the incidence of about 1 % in various population groups, 
and three of them were shown to affect physiological and pathophysiological processes. This review summarises current 
knowledge about these three SNPs in the MT2A gene and their associations with element concentrations in the body of 
healthy and diseased persons. The most investigated SNP is rs28366003 (MT2A −5 A/G). Reports associate it with 
longevity, cancer (breast, prostate, laryngeal, and in paranasal sinuses), and chronic renal disease. The second most 
investigated SNP, rs10636 (MT2A +838G/C), is associated with breast cancer, cardiovascular disease, and type 2 diabetes. 
Both are also associated with several metal/metalloid concentrations in the organism. The third SNP, rs1610216 (MT2A 
−209A/G), has been studied for association with type 2 diabetes, cardiomyopathy, hyperglycaemia, and Zn concentrations. 
Metallothionein concentrations and MT2A polymorphisms have a potential to be used as biomarkers of metal exposure 
and clinical markers of a number of chronic diseases. This potential needs to be studied and verified in a large number of 
well-defined groups of participants (several hundreds and thousands) with a focus on particular physiological or pathological 
condition and taking into consideration other contributing factors, such as environmental exposure and individual genetic 
and epigenetic makeup.
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Pollution has been recognised as a major global health 
threat. Although exposure to various pollutants, including 
toxic metals or mixtures of environmental stressors is 
widespread, the development of diseases caused by direct 
environmental exposure is, luckily, limited. Whether the 
disease develops will depend on the causative agent, 
exposure levels and duration, the period of life when 
exposure occurs, age, and sex. Other factors that may 
contribute to the development and progression of a disease 
include other condition or disease, dietary habits, physical 
activity, medications taken, and variation in genetic 
susceptibility (1–3).
In the course of our continuing study of the exposure, 
health risks, and effects of the main toxic and essential 
elements lead (Pb), cadmium (Cd), mercury (Hg), arsenic 
(As), zinc (Zn), copper (Cu), iron (Fe), and selenium (Se), 
we recently came across increasing evidence of a link 
between the levels of these elements in the body of healthy 
and diseased persons and specific gene polymorphisms of 
metallothioneins (MTs). This motivated us to prepare an 
overview of the relationships between element levels and 
three most studied single nucleotide polymorphisms (SNPs) 
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of the MT2A gene, namely rs28366003, rs1610216, and 
rs10636. For the purpose of this review, we searched 
PubMed database for articles indexed until the end of 2019 
using this keyword combination: metallothionein AND 
polymorphism AND human. The query yielded 113 
matches, and the first article on specific MT2A polymorphism 
was from 2005. We excluded 13 review articles, two letters 
to the editor, and 62 articles dealing with SNPs other than 
MT2A. This review has no intention whatsoever to present 
these gene polymorphisms as either the main or only 
contributing factors to element levels in the human body 
or to the development of chronic diseases, including 
malignancies, nor does it go into detail of the reported 
studies. Instead we compare their findings in a series of 
tables and comment on the relationships between 
rs28366003 and toxic metal levels in the human body only 
where we compare them with our own findings (4).
BIOLOGICAL SIGNIFICANCE OF 
METALLOTHIONEINS
Metallothioneins are a superfamily of cysteine-rich, 
intracellular, metal-binding proteins present in plants, 
vertebrates, invertebrates, eukaryotes, and prokaryotes. 
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Historically, the discovery of MTs has closely been related 
to the study of Cd. The earliest work in this area was 
reported in 1941 by Maliuga, whereas the data on Cd-
binding protein isolated from equine renal cortex, later 
named metallothionein, were first reported by Margoshes 
and Vallee in 1957 (reviewed in 5–9). Since then, MT has 
been of great interest in many scientific disciplines, 
including toxicology, biological and physical chemistry, 
molecular biology, and various clinical and cancer studies 
with about 10,000 published papers (7–9). The characteristics 
of MTs are low molecular mass of 6–7 kDa, high cysteine 
content (about 30 %), no aromatic amino acid, and high 
binding affinity for metals, particularly for Zn, Cu, and Cd. 
The amounts and ratios of metals bound by the thiol (–SH, 
mercaptide) group will depend on the tissue; human liver 
MTs mostly contain Zn and small amounts of Cu, while 
renal cortex MTs mostly contain Cd, then Zn, and then Cu 
(reviewed in 5, 8–12).
In mammals, including humans, there are four main 
groups of MTs with different sequences, expression, and 
characteristics: MT1, MT2, MT3, and MT4. Isoforms MT1 
and MT2 are expressed in almost all tissues. MT3 is 
expressed mainly in the brain, and to a lesser extent in the 
heart, kidneys, and reproductive organs (reviewed in 8–10, 
13–15). MT4 is expressed in the epithelial cells of the skin 
and mucosa (16). MT molecules are single-chain 
polypeptides, which contain 61 to 68 amino acids, and 20 
of them are cysteine, ordered in the sequences Cys-Cys, 
Cys-x-Cys, and Cys-x-y-Cys (x and y are amino acid which 
are not cysteine) (8–10, 17). Cysteine sulphur atoms are 
responsible for binding divalent metals in two clusters of 
MTs, connected with a sequence which does not contain 
cysteine. Amino acids 1 to 30 form a stable α-cluster 
(C-terminal) with four metal binding sites, whereas amino 
acids 31 to 68 form a reactive β-cluster (N-terminal) with 
three binding sites for divalent metals ions. Therefore, each 
MT molecule can bind up to seven divalent ions of Zn, Cd, 
Hg, and Pb, 12 of Cu, and 18 of Ag. Four metal ions first 
fill the α-cluster, and remaining three ions enter the β-cluster. 
Metals bound to the β-cluster are released more easily than 
metals bound to the α-cluster (8, 10, 13, 15, 18). The order 
of metal-binding affinities was tested by in vitro studies on 
rat liver in the 1980s and the reports are not uniform: 
C d > P b > C u > H g > Z n > A g > N i = C o  ( 1 9 ) , 
Hg>Cu>Cd>Zn>Ni=Co (20), and Hg>Ag>>Cu>Cd> Zn 
(21). Many metals have the affinity for MT but only Cu+, 
Cd2+, Pb2+, Ag+, Hg2+, and Bi2+ can displace Zn2+ in MT, 
which was confirmed in the horse kidney in vitro (22) and 
in the rat liver in vivo studies (23). Exchanges between Zn 
and Cd happen rapidly in the β-cluster, contrary to their 
slow exchange in the α-cluster. Zinc readily dissociates 
from MT to make itself available for different biological 
functions and to stimulate further MT synthesis. 
Metallothioneins serve as metal ion donors to other ligands 
or proteins (reviewed in 13, 24, 25). Their degradation 
depends on metals bound, their distribution in MT 
molecules, and the medium. Acidic media are known to 
speed up metal dissociation from MTs. MTs completely 
saturated with metals are more resistant to degradation by 
lysosomal proteases than unsaturated MTs or apothioneins 
(apo-MTs, that is MTs free of metals). In neutral media, 
MTs saturated with metals are less resistant to degradation 
than apo-MTs (25–28).
The synthesis of MTs is induced by numerous factors 
such as metals and metalloids, various chemical agents, 
including acetaminophen (paracetamol), cytokines, and 
many other stress-producing conditions, including oxidative 
stress, infection and inflammation. The peculiar chemical 
structure of MTs gives them their molecular stability and 
specificity and defines their role in various physiological 
and pathological conditions (8–11, 29–33). Their main 
biological function is to maintain the homeostasis of 
essential metals Zn and Cu (reviewed in 12). Studies 
conducted in vitro showed reactivation of apo-enzymes in 
which Zn or Cu were cofactors (alkaline phosphatase, 
superoxide dismutase and others) after incubation with 
Zn-MT or Cu-MT. The mechanism of Zn donation from 
MT to apo-enzyme is still unknown, but it is assumed that 
MT binds to an MT-releasing factor, which displaces Zn 
and makes it available to enzymes (8, 14). It has been shown 
that MTs participate in Zn regulation by intestinal absorption 
and excretion. When Zn intake is high, MTs may have a 
crucial role in restricting its absorption by storing it in the 
enterocytes and enabling its transfer back to the gut lumen, 
as confirmed by studies on knockout and transgenic mice 
(34–39). The induction of intestinal MT by Zn and its 
interaction with Cu is used in the therapy of patients with 
Wilson’s disease with Zn acetate, a US Food and Drug 
Administration-approved drug. Wilson’s disease is a rare 
autosomal recessive inherited disorder of Cu metabolism 
characterised by the accumulation of excessive amounts of 
Cu in the liver, brain, and eyes. The mechanism of Zn action 
as an anti-copper agent involves inhibition of both Cu 
absorption from the gastrointestinal tract and its transfer 
into the circulation by capturing the Cu-MT complex in the 
mucosal cell and its ultimate faecal excretion (40, 41).
Metallothioneins have multiple roles. Besides its main 
function to keep essential elements in balance, they protect 
the body against free radicals and toxic effects of metal ions 
(reviewed in 8–10, 13, 24, 42−46). High levels of MTs can 
be found in foetal and neonatal liver, but these drop to the 
levels found in adults during the postnatal period. Increased 
liver MT levels during prenatal period in all mammalian 
species are believed to protect against potentially toxic Zn 
and Cu ions before the intestinal control mechanisms 
develop (46−49). Another important role of MTs is to 
protect against oxidative stress caused by various 
environmental stressors, including toxic metals. 
Experimental studies showed lower acute hepatotoxicity of 
Cd due to induced MT synthesis and high Cd binding to 
cytosolic MT, which reduces exposure of target organelles 
to Cd (reviewed in 32). Studies conducted on knock out 
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mice showed that those without MT expression were more 
sensitive to Cd toxicity than control mice. The protective 
effects of MTs are generally clear against acute metal 
toxicity and carcinogenicity but not as much against chronic 
metal toxicity, to be addressed later in the text (8, 50–52). 
In general, large amounts of –SH groups in MT molecule 
enable reaction with numerous electrophilic chemicals, as 
they catch free radicals such as hydroxyl, superoxide or 
nitric oxide radicals produced during metabolism of 
xenobiotics (33, 53, 54–57).
Other important roles of MTs involve cell survival, 
inhibition of apoptosis, angiogenesis and vascular 
remodelling, and immunomodulation. Studies on human 
umbilical vascular endothelial cells (HUVECs) have shown 
that a homedomain protein HMBOX1, which acts as a 
transcription factor and is abundantly expressed in the 
cytoplasm of the endothelial cells, maintains cell survival 
by promoting autophagy and inhibiting apoptosis by 
interaction with MT2, which increases intracellular free Zn 
(58). This role of MTs in vascular remodelling is important 
in the development of atherosclerosis and malignant 
tumours. Furthermore, MTs seem to inhibit pro-inflammatory 
cytokines, such as interleukins IL-6 and IL-12 and tumour 
necrosis factor TNF-α, and can therefore supress 
inflammation (59). Investigations on MT-null mice showed 
higher susceptibility to the hepatotoxic effects of the anti-
inflammatory drug paracetamol (acetaminophen), which 
points to the protective role of MTs against chemically 
induced hepatotoxicity (60, 61). The protective antioxidant 
role of MTs against radiation-mediated immunosuppression 
and cell damage was confirmed in experiments on MT-null 
mice (62, 63).
REGULATION OF METALLOTHIONEIN 
SYNTHESIS AND MT2A POLYMORPHISMS
Synthesis of MTs in humans is encoded by a cluster of 
genes located in the q13 locus of chromosome 16 (16q13). 
Until now, 17 genes have been identified in this cluster, and 
at least 11 of them are functional; eight among MT1 
isoforms (MT1A, MT1B, MT1E, MT1F, MT1G, MT1H, 
MT1M/MT1K, and MT1X), and the other three have only 
one functional gene (MT2A, MT3, and MT4) (reviewed in 
8–12, 15, 45, 64–67). The genes consist of two to three 
exons and one to two introns. Elements that control MT 
transcription can be divided in basal and inducible. The 
basal elements of gene sequence are the TATA-box, GC-
box, and at least two basal level enhancer (BLE) sequences. 
The promoter region of the MT1 and MT2 genes involve 
inducible elements that consist of different types of 
responsive elements: metal response elements (MREs), 
glucocorticoid response elements (GREs), and antioxidant 
response elements (AREs). The most investigated 
mechanism of MT gene transcription by metal ions is via 
several MREs located in 5’ untranslated region (UTR) of 
the gene (67–69). Early studies showed that metal 
transcription factor 1 (MTF-1) binds to MREs in the 
promoter regions of MT genes via Zn finger transcription 
(Cys2-His2) factor controlling the expression of the MT1 
and MT2 genes. Besides Zn, MTF-1 can be activated by 
reactive oxygen species, tyrosine-specific protein kinase, 
protein kinase C, and c-Jun N-terminal kinase (68–72).
Metal ions other than Zn can induce MT synthesis by 
mechanisms different than the one described above. Toxic 
metals cannot activate MTF-1 and, due to high binding 
affinity for MT, they replace Zn ions in MT molecules and 
thus increase intracellular Zn levels (reviewed in 13–15, 
24). Free Zn then stimulates further synthesis of MT by 
binding to MTF-1, which then binds to MRE and ultimately 
has impact on metal toxicity. In other words, under 
conditions of acute exposure to high doses of toxic metals 
such as Cd or Hg, higher MT expression may reduce their 
toxicity. However, in chronic exposure to either of the toxic 
metals (Cd or Hg), increased MT synthesis leads to 
prolonged retention of that metal in the body, which 
increases the risk of toxic effects. In addition, increased MT 
may capture essential elements in internal organs, primarily 
Zn in the liver, making them less available for their 
physiological roles such as transfer to the developing foetus 
through placenta during pregnancy (reviewed in 8, 73).
Metallothionein expression can be induced by oxidative 
stress when generated hydrogen peroxide (H2O2) radicals 
oxidise MT, and Zn is released, which then activates MTF-
1 (64). Glucocorticoids also regulate MT transcription by 
binding to their response elements (GREs) in the promoter 
region of the MT genes (74). MT expression can be also 
induced also by tissue hypoxia (75), catecholamines (76), 
or hypothermia (77).
Single nucleotide polymorphisms (SNPs) are genetic 
variations characterised by the replacement of one 
nucleotide with another in a certain stretch of DNA, which 
occurs in at least 1 % of the population and differs between 
population groups. Given their location, SNPs can either 
be in the coding or non-coding gene region. Those in the 
coding region may affect amino acid arrangement or 
influence protein kinetics, mRNA structure, and stability, 
while SNPs in the promoter region or other regulatory gene 
regions affect protein production (reviewed in 67, 78). 
According to the National Center for Biotechnology 
Information (NCBI) database on polymorphism, dbSNP 
(79), 24 polymorphisms in the MT2A gene have been 
identified in humans, three of which may affect physiological 
and pathophysiological processes. The most studied SNP 
in MT2A was rs28366003 (−5A/G), followed by rs10636 
(+838G/C), whereas rs1610216 (−209A/G) has been the 
least investigated. Only Starska et al. (80, 81) and Krześlak 
et al. (82) studied all three MT2A SNPs and their associations 
with several malignant tumours in a Polish population.
Below we describe these and other information about 
MT2A polymorphisms with the focus on reported 
relationships with trace elements. We set up three sets of 
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interrelated tables, in which we present the following groups 
of data for each SNP: 1) literature data on the related 
genotype frequencies; 2) reported associations with human 
diseases; and 3) reported associations with element 
concentrations in humans. Of the 36 selected references, 
21 deal with relationships with elements (in healthy and/
diseased persons), 13 with diseases only, and two with 
genotype frequencies only.
MT2A polymorphism rs28366003
The rs28366003 (MT2A −5A/G) SNP is an A/G 
substitution that occurs in the core promoter region of the 
MT2A gene between the TATA box and the site where the 
transcription begins. As it occurs near 5’UTR, it can affect 
MT transcription through reduced MTF-1 binding on MRE 
(reviewed in 11, 67). A study on human embryonic kidney 
cells 293 (HEK 293) showed that substitution of the A allele 
with the G allele near 5’UTR reduced Cd-induced 
transcription. Reduced MT transcription can therefore affect 
element concentrations in the body and adversely affect 
health (46, 83).
Studies of the rs28366003 SNP were mostly conducted 
in Turkish and Polish populations, but several were also 
done in Japan and the United States, China, Thailand, Spain, 
and Croatia. Table 1 shows the frequencies of AA, AG, and 
GG genotypes reported in these studies. According to the 
literature data, the frequency of the AA genotype ranges 
from 84.0 % to 95.5 % in healthy Polish (80–82, 84–88), 
86.0 % to 90.4 % in Turkish (89–94), and about 82 % in 
Japanese population (95, 96). The highest frequencies were 
found in a healthy Spanish population (97.9 %) (97), US 
black women (97.9 %) (98), Croatian women (93–94.0 %) 
(4, 99), and a healthy Chinese population (92.5 %) (100). 
The lowest frequency of 57.8 % and 53.4 % was found in 
healthy Iranian and Columbian populations, respectively 
(101, 102). The frequency of the AG ranged from 2.1 % in 
healthy Spanish population (97) and black US women (98) 
to 37.8 % and 43.6 % in Iranian and Columbian population, 
respectively (101, 102). We conducted the first study of that 
kind in Croatia and found that nearly 6 % of the healthy 
postpartum women were G allele carriers (4). Several 
authors reported higher percentages of G allele carriers in 
case study groups than controls (80, 84, 97, 100), and others 
reported no differences (88, 96). Higher frequency of AG 
genotype was reported among white (12.8 %) than black 
(2.1 %) women in the USA (98).
Table 2 summarises associations between the 
rs28366003 SNP and various clinical entities reported in 
literature. The associations were found for different types 
of cancers in the breast, prostate, paranasal sinus, larynx 
and stomach (31, 80–82, 84–87, 100, 101) and chronic 
diseases, such as type 2 diabetes mellitus, chronic kidney 
disease (95), and neovascular and dry forms of age-related 
macular degeneration (97). Several studies reported no 
association between rs28366003 SNP and prostate cancer 
(88), type 2 diabetes mellitus (103), or sporadic amyotrophic 
lateral sclerosis (96).
Table 3 summarises association between rs28366003 
SNP and element levels in various healthy population 
groups or subjects with defined disease. These findings are 
controversial, as a number of studies found correlations 
with element concentrations in the human organism (84–86, 
89–91, 104) and others did not (95, 99, 102, 105, 106).
In our recent study in healthy Croatian postpartum 
women (4) we found no significant association between 
rs28366003 and either Cd or Pb concentrations in the 
placenta and maternal and cord blood, although stepwise 
multiple regression analysis showed marginal contribution 
of this SNP to higher placental Cd and Pb, maternal Pb, and 
cord blood Cd concentrations. We did find lower placental 
Fe in non-smoking G allele carriers (persons with AG and 
GG genotype) than non-smoking persons with the wild AA 
genotype, which surprised us at first, as Fe-MT binding has 
mostly been underestimated in literature (reviewed in 107). 
This result can be at least partly explained by the links 
between MT and Fe. Conditions of an acidic lysosomal-like 
environment created in vitro can stimulate MT release of 
Zn or Cu, which increases MT expression and facilitates 
Fe-MT binding (108). Through this mechanism, MT may 
protect from lysosomal destabilisation due to Fe overload-
induced oxidative stress (reviewed in 109). In contrast to 
our study in Croatian population (n=268), studies in Turkish 
population (89, 90) reported higher Cd (n=95) and Pb 
(n=91) concentrations in maternal blood, higher Fe in the 
umbilical cord blood, lower Cd in the placenta, and no 
difference in placental Fe concentrations in non-smoking 
G allele carriers vs. persons with the wild AA genotype. 
However, those studies report an odd discrepancy between 
high blood and low placental Cd levels. Blood Cd was much 
higher than reported earlier in non-smoking Turkish 
population (110) and placental Cd was at the lower end of 
the scale of the overall placental Cd levels ever measured 
and reported in literature between 1976 and 2011 (111). 
These findings point to an unidentified source of Cd and/
or analytical error, which may have blurred the association 
between rs28366003 and metal concentrations. Since 
studies on the association between this SNP and toxic and 
essential elements in mother-newborn pairs are inconsistent, 
further research is needed with a large number of subjects 
(after either spontaneous delivery or Caesarean section) 
with defined sources of exposure to toxic metals, including 
cigarette smoking and dietary habits, as they all may 
overcome the influence on element levels of this or the other 
two discussed MT2A SNPs , which, as a rule, have low 
genotype frequency at the population level. Table 3 shows 
that population studies of the association between 
rs28366003 and element levels to date have included 
between 100 and 700 participants. The only exception is 
the Japanese study (95), which included >2700 participants. 
More such studies with large population samples are needed.
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Table 1 Genotype frequencies of the rs28366003 (MT2A −5A/G) single nucleotide polymorphism in humans
Authors and year of 
publication  
(reference No.)
Ethnicity n Study participants
Genotype frequencies (%)
AA AG GG
Stajnko et al., 2019 
(99)
Croatian 136 Pregnant women 93.0# 7.0$
Slovenian 176 Non-pregnant women 95.0# 5.0$
Shokrzadeh et al., 2019 
(101) Iranian
95 Men and women with gastric cancer 46.4 41.0 12.6
90 Control healthy men and women 57.8 37.8 4.4
Sekovanić et al., 2018 (4) Croatian 268 Mother-newborn pairs 94.0 6.0§
González-Martínez et 
al., 2018 (102) Colombian 101 Men and women 53.4 43.6 3.0
Białkowska et al., 2018 
(88) Polish
197 Men with prostate cancer 90.9 9.1§
197 Control men without prostate cancer 89.3 10.7§
Yang et al., 2017 (105) Thai 677 Men and women 79.5 20.5 0.0
Liu et al., 2017 (100) Chinese
459 Women with breast cancer (various types) 82.3 15.3 2.4
549 Control healthy women 92.5 7.5 0.0
García et al., 2017 (97) Spanish
130 Men and women with AMD 88.5 11.5 0.0
96 Control healthy men and women 97.9 2.1 0.0
Raudenska et al., 2017 
(103) Czech
70 Men and women with type 2 diabetes mellitus 88.6 8.6 0.0
80 Control healthy men and women 86.3 13.7 0.0
Hattori et al., 2016 (95) Japanese 2774 Men and women 81.8 17.4 0.8
Adams et al., 2015 
(104) US
170 Premenopausal women 88.0 12.0 0.0
151 Men and women 84.0 15.0 1.0
Starska et al., 2015 (80) Polish
130 Men and women with SIP 75.4 23.8 0.8
418 Control men and women without head or neck tumour 95.5 4.1 0.0
Starska et al., 2015 (84) Polish
117 Men and women with SIP 76.1 23.1 0.8
132 Control men and women with normal sinonasal mucosa 87.9 12.1 0.0
Starska et al., 2014 (85) Polish
323 Men and women with SCC 89.2 9.9 0.9
116 Control men and women with normal laryngeal mucosa 84.5 14.6 0.9
Starska et al., 2014 (81) Polish
323 Men and women with laryngeal cancer 89.2 9.9 0.9
418 Control healthy men and women 84.0 16.0 0.0
Krześlak et al., 2014 
(82) Polish
534 Women with ductal breast cancer 87.1 12.3 0.6
556 Control healthy women 92.8 7.2 0.0
Krześlak et al., 2013 
(86) Polish
412 Men with prostate cancer 76.0 21.1 2.9
67 Control men without prostate cancer 88.0 12.0 0.0
Wang et al., 2012 (106) US 239 Men and women 89.1 10.1 0.8
Forma et al., 2012 (87) Polish
358 Men with prostate cancer 76.8 20.9 2.3
406 Control men without prostate cancer 88.9 10.6 0.5
Tekin et al., 2012 (89) Turkish 95 Mother-newborn pairs 87.4 12.6 0.0
Tekin et al., 2012 (90) Turkish 91 Mother-newborn pairs 86.8 13.2 0.0
Kayaalti et al., 2011 (91) Turkish 616 Men and women 86.6 12.8 0.6
Kayaalti et al., 2011 (92) Turkish 354 Men and women 90.4 9.0 0.6
McElroy et al., 2010 
(98) US
142 Black women 97.9 2.1 -
149 White women 87.3 12.8 -
Kayaalti et al., 2010 
(93) Turkish
122 Men and women (kidney samples) 88.5 10.7 0.8
186 Men and women (blood samples) 86.0 13.4 0.6
Kayaalti et al., 2010 (94) Turkish 114 Men and women (kidney samples) 87.7 11.4 0.9
Hayashi et al., 2006 
(96) Japanese
37 Patients with SALS 75.7 24.3 0.0
206 Control healthy men and women 82.5 17.0 0.5
n – sample size; AA – typical homozygote; AG – heterozygote; GG – atypical homozygote; AMD – age-related macular degeneration; 
SIP – sinonasal inverted papilloma (Schneiderian papilloma); SCC – squamous cell laryngeal carcinoma; SALS – sporadic amyotrophic 
lateral sclerosis; #A allele frequency; $G allele frequency; §G allele carriers (AG plus GG genotype)


























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































The rs1610216 (MT2A −209A/G) SNP also occurs in 
the promoter region. Unlike rs28366003, however it has 
received considerably less attention and most of the studies 
were done in Polish population. Table 4 summarises its 
genotype frequencies. The frequencies of the AA, AG, and 
GG genotype in healthy Polish population ranged from 
72.0 % to 73.9 %, 25.3 % to 27.8, and 0.2 % to 0.8 %, 
respectively (80–82, 87). Similar AA genotype frequencies 
were reported for healthy Italian population, while their GG 
genotype frequencies were somewhat higher, from 3.0 % 
to 3.7 % (112, 113). The highest AA genotype frequency 
of 90.5 % was reported in healthy Bulgarian population 
(114). The same study also reported higher percentage of 
the AG genotype in patients with type 2 diabetes mellitus 
and coronary artery disease than in healthy persons.
Table 5 shows the association between MT2A rs1610216 
and human diseases. Studies conducted in Polish population 
found no association between rs1610216 and either 
Schneiderian papilloma or laryngeal cancer (80, 81). No 
associations were also reported for this SNP and breast or 
prostate cancers (82, 87), carotid artery stenosis and 
hypertension (112, 113), or coronary artery disease (114). 
Positive association was reported with type 2 diabetes 
mellitus (114) and subjects with the AA genotype ran a 
higher risk of ischaemic cardiomyopathy and hyperglycaemia 
(112). There are no data on association between the 
rs1610216 SNP and element concentrations in human 
organism, except the one study (112) dealing with an 
association between this SNP and Zn in plasma (Table 6).
MT2A rs10636 polymorphism
The rs10636 (MT2A +838G/C) SNP occurs in the 
3’UTR. Genotype frequencies of this SNP are presented in 
Table 7. The frequencies of the GG genotype range from 
42.9 % in Chinese (115) to 67.7 % in healthy Spanish 
population (97). Healthy Chinese population had the highest 
percentage of the CC genotype (9.7 %) (115), whereas the 
US and Polish populations had the lowest frequency (about 
4.0 %) (82, 104). The only study that reported genotype 
frequencies of the rs10636 SNP in children was in boys and 
girls with the mean age of 10 years in Portugal, a country 
known for increased Hg intake through seafood/fish 
consumption and the risk of related neurotoxic effects in 
both sexes at young age (116).
Table 8 summarises the findings on associations 
between rs10636 and diseases. This polymorphism may be 
associated with higher incidence of neuropathy and 
hyperlipidaemia in patients with type 2 diabetes mellitus 
(115), coronary heart disease (117), and breast cancer (100). 
Krześlak et al. (82) found no association with ductal breast 
cancer. No association was also reported between rs10636 
and macular degeneration related to age (97), Schneiderian 
papilloma, or laryngeal cancer (80, 81). Giacconi et al. (113) 
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reported that in the C allele carriers carotid artery disease 
was more likely to progress to carotid artery stenosis. 
The associations between this polymorphism and 
element concentrations in human organism are presented 
in Table 9. A weak association was reported for blood Cd 
in healthy women exposed to Cd (118). Although Hg was 
not associated with the CC genotype, a multivariate analysis 
indicated lower Hg in urine in subjects with the CC 
genotype than those with the GG genotype (106). C allele 
carriers were found to have lower concentrations of Cd, Cu 
and Zn in urine (104), Pb in blood (119, 120), and Fe in 
plasma (113) and higher Zn and Cu in red blood cells (113).
CONCLUDING REMARKS
There is strong evidence that MTs participate in 
physiological and pathological processes in the human body 
which involve the homeostasis of intracellular essential 
element, primarily Zn and Cu. They may chelate divalent 
toxic metals, such as Cd, Pb, Hg, or Pt with the –SH groups 
in cysteine and thus detoxify cells, scavenge free radicals, 
and protect cells against oxidative stress. They also have a 
role in cell survival and proliferation, angiogenesis, and 
inhibition of apoptosis. Emerging evidence confirms that 
MT insufficiency may lead to pathogenic processes and 
carcinogenesis. Single gene polymorphisms of MTs may 
be responsible for individual differences in reactions to 
harmful effects of external chemical and physical stressors 
and reactive oxygen species in the body.
Identification of individual MT isoforms in human cells 
and tissues can be applied in prospective tissue, plasma, 
and urine analyses or retrospectively, using fixed paraffin-
embedded tissue samples. In the future, MTs may serve as 
biomarkers of environmental exposure to toxic metals, such 
as Cd, as already reported in biomonitoring studies on 
occupational exposure in humans (121−123) or 
environmental exposure in animals (124−126). MTs are 
also intensively studied as potential clinical biomarkers to 
be used in the diagnosis, prognosis, and selection of efficient 
therapy/ies for a number of malignant tumours, such as 
breast, thyroid, head, neck, lung, gallbladder, pancreas, 
colon, kidney, ovary, prostate, bone, and skin cancers, 
childhood solid tumours, and various types of leukaemia 
(29−32, 82, 86, 87, 94, 127–132). Exogenous MTs are 
already being investigated for the treatment of pathological 
processes in the central nervous system (59).
To date, the rs28366003, rs10636, and rs1610216 SNPs 
in the MT2A gene have been associated with various 
physiological and pathological conditions. These involve 
ageing and chronic diseases, such as metabolic syndrome 
(including type 2 diabetes mellitus and obesity), 
cardiovascular diseases, osteoporosis, and psychiatric 
disorders. They also seem to interfere with the effects of 
toxic drugs and pollutants. However, their use as risk 
predictors remains controversial. Identifying a single 
specific allelic variant associated with an individual trait, 
health or disease by gene-specific, candidate-driven studies 
(133) may fail to provide full information and risk 
assessment of certain diseases, which, as a rule, have 
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Table 4 Genotype frequencies of the rs1610216 (MT2A −209A/G) single nucleotide polymorphism in humans
Authors and year 
of publication 
(reference No.)
Ethnicity n Study population
Genotype frequencies (%)
AA AG GG
Starska et al., 2015 
(80) Polish
130 Men and women with SIP 73.8 25.4 0.8
418 Control men and women without head and neck tumours 73.9 25.3 0.8
Starska et al., 2014 
(81) Polish
323 Men and women with laryngeal cancer 73.4 26.0 0.6
418 Control healthy men and women 73.9 25.3 0.8
Krześlak et al., 
2014 (82) Polish
534 Women with breast cancer 76.4 23.4 0.2
556 Control healthy women 72.3 27.5 0.2
Forma et al., 2012 
(87) Polish
358 Men with prostate cancer 71.8 27.6 0.6
406 Control men without prostate cancer 72.0 27.8 0.2
Kozarova et al., 
2012 (114) Bulgarian
142 Patients with CAD 89.2 9.4 1.4
101 Patients with DM 69.7 28.3 2.0
61 Control healthy volunteers 90.5 0.0 9.5
Giacconi et al., 
2007 (113) Italian
100 CS patients 75.0 24.0 1.0
188 CS patients without cerebrovascular episodes 73.0 25.0 2.0
218 Control elderly volunteers 71.0 26.0 3.0
Giacconi et al., 
2005 (112) Italian
91 Men and women with carotid stenosis 86.0 14.0 0.0
188 Control elderly men and women 70.2 26.1 3.7
n – sample size; AA – typical homozygote; AG – heterozygote; GG – atypical homozygote; SIP – sinonasal inverted papilloma 
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polygenic origins (134, 135) and therefore need genome-
wide association studies (136, 137). More comprehensive 
studies are needed to determine the role and potential for 
the clinical use of specific MT2A gene polymorphisms. 
These should recruit a large number of participants (several 
hundreds and more) with well-defined pathological process 
and take into account other factors and risks, such as specific 
environmental exposure and personal habits, genetic 
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Table 7 Genotype frequencies of the rs10636 (MT2A +838G/C) single nucleotide polymorphism in humans
Authors and year 
of publication 
(reference No.)
Ethnicity n Study participants
Genotype frequencies (%)
GG GC CC
Yang et al., 2017 (105) Thai 677 Men and women 52.4 41.6 6.0
Liu et al., 2017 (100) Chinese
459 Women with breast cancer 52.5 37.5 11.8
549 Control healthy women 52.8 40.8 6.4
García et al., 2017 
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Adams et al., 2015 
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151 Men and women 62.0 34.0 4.0
Starska et al., 2015 
(80) Polish
130 Men and women with SIP 44.6 43.1 12.3
418 Control men and women without head and neck tumours 50.9 41.2 7.9
Starska et al., 2014 
(81) Polish
323 Men and women with laryngeal cancer 45.8 46.1 8.1
418 Control volunteers (men and women) 50.9 41.2 7.9
Yang et al., 2014 
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(82) Polish
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556 Control healthy women 50.3 45.5 4.2
Woods et al., 2013 
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163 Boys average age 10 years 61.3 30.7 8.0
167 Girls average age 10 years 59.9 33.5 6.6
Chen et al., 2012 (118) Chinese 465 Men and women 52.3 39.5 8.2
Wang et al., 2012 (106) US 464 Men and women 54.1 36.8 9.1
Forma et al., 2012 
(87) Polish
358 Men with prostate cancer 48.9 43.3 7.8
406 Control men without prostate cancer 52.0 40.0 8.0
Gundacker et al., 
2009 (120) Austrian 180 Men and women 58.4 33.3 8.3
Yang et al., 2008 
(115) Chinese
182 Men and women with DM 46.7 42.9 10.4
196 Control volunteers (men and women) 42.9 47.4 9.70
Giacconi et al., 2007 
(113) Italian
100 CS patients 73.0 22.0 5.0
188 CS patients without cerebrovascular episodes 66.0 30.0 4.0
218 Control elderly volunteers 56.0 37.0 7.0
n – sample size; MT2A – metallothionein 2A; GG – typical homozygote; GC – heterozygote; CC – atypical homozygote; AMD – age-
related macular degeneration; SIP – sinonasal inverted papilloma (Schneiderian papilloma); CHD – coronary heart disease; DM – 
diabetes mellitus; CS – carotid artery stenosis
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Polimorfizmi gena metalotioneina 2A u ljudi i njihova povezanost s bolestima i razinama elemenata u tragu
Metalotioneini u ljudskom organizmu povezana su skupina niskomolekularnih unutarstaničnih proteina, čiju sintezu mogu 
pobuditi esencijalni elementi, ponajprije Zn i Cu, toksični elementi i druge kemijske tvari te razni uvjeti koji izazivaju 
stres u organizmu. Od četiriju poznatih izoformi metalotioneina u ljudskome tijelu, najčešći oblik je MT2. Izražaj 
metalotioneina kodira skupina povezanih gena i na to mogu utjecati polimorfizmi pojedinačnoga nukleotida u tim genima. 
Do sada su otkrivena 24 jednonukleotidna polimorfizma u području gena MT2A, s incidencijom od oko 1 % u raznim 
skupinama stanovništva, a za tri je takva polimorfizma utvrđeno da bi mogli utjecati na fiziološke i patofiziološke procese. 
U preglednom radu prikazane su dosadašnje spoznaje o trima jednonukleotidnim polimorfizmima u genu MT2A i njihove 
povezanosti s koncentracijama elemenata u zdravih i bolesnih osoba. Najviše istraživan jednonukleotidni polimorfizam 
gena MT2A do sada bio je rs28366003 (MT2A −5A/G) i za njega su pokazane povezanosti s duljinom života, nekoliko 
tipova karcinoma (u dojki, prostati, grkljanu i sinusima) i s bubrežnim bolestima. Za drugi najviše istraživani polimorfizam 
rs10636 (MT2A +838G/C) nađene su povezanosti s rakom dojke, bolestima srca i krvnih žila te dijabetesom tipa 2. Za 
obje te vrste polimorfizama nađene su povezanosti i s koncentracijama metala i polumetala u organizmu. U samo nekoliko 
istraživanja ispitivana je povezanost polimorfizma rs1610216 (MT2A −209A/G) s dijabetesom tipa 2, kardiomiopatijom, 
hiperglikemijom i koncentracijama Zn. Podatci u literaturi upućuju na moguću praktičnu primjenu nalaza koncentracija 
metalotioneina i genskih polimorfizama MT2A kao bioloških pokazatelja izloženosti metalima i kliničkih pokazatelja 
brojnih kroničnih bolesti. Za tu svrhu potrebna su daljnja opsežna istraživanja u velikom broju dobro definiranih skupina 
ispitanika (nekoliko stotina i tisuća), usredotočenih na određeno fiziološko ili patološko stanje te uzimajući u obzir druge 
čimbenike, kao što su okolišna izloženost, osobne životne navike te genetičke i epigenetičke značajke. 
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